Eligible Cancer Types

OCTANE 1.0

We are enrolling patients with advanced, incurable solid tumors. As of December 2022, we have enrolled more than 5000 patients with advanced solid tumors, with the largest group being gynecological cancers followed by breast, colorectal, and pancreatobiliary (pancreas, bile duct, gallbladder, ampullary) cancers.

picture of a graph of octan 1.0 cancer types

OCTANE 2.0

The second stage of this study will enroll participants with specific types of cancer into two broad categories:

  1. Treatment Resistance: patients with advanced-stage cancers including:
    • Cutaneous melanoma (advanced/metastatic disease) patients treated with immune checkpoint inhibitor (ICI) therapy
    • Non-small cell lung cancer (advanced/metastatic disease) patients treated with ICI therapy
    • Translocation-associated sarcoma patients
  2. Minimal Residual Disease: early-stage patients treated with curative intent with a high risk of their cancer returning.
    • Cutaneous melanoma (stage III) patients treated with adjuvant PD-1 ICI following surgery
    • Non-small cell lung cancer (stage III) patients treated with chemoradiotherapy followed by adjuvant ICI
    • Breast cancer (stage II/III estrogen receptor-negative) patients treated with neoadjuvant chemotherapy +/- HER2-targeted therapy
    • Advanced solid tumor oligometastases patients treated with ablative radiotherapy
    • Soft tissue sarcoma patients undergoing metastatectomy

Glossary

Return Home
Icons made by Freepik from www.flaticon.com is licensed by CC 3.0 BY